日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

fSCIG 10% 用于儿童原发性免疫缺陷疾病：一项欧洲上市后安全性研究

期刊:Allergy Asthma and Clinical Immunology
影响因子:2.4
doi:10.1186/s13223-024-00904-9
Čižnár, Peter; Roderick, Marion; Schneiderova, Helen; Jeseňák, Miloš; Kriván, Gergely; Brodszki, Nicholas; Jolles, Stephen; Atisso, Charles; Fielhauer, Katharina; Saeed-Khawaja, Shumyla; McCoy, Barbara; Yel, Leman
免疫/内分泌
发表日期：2024
文献求助 收藏

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

REWIND 研究探索度拉糖肽对 2 型糖尿病患者心血管获益的潜在介质

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-021-01386-4
Konig, Manige; Riddle, Matthew C; Colhoun, Helen M; Branch, Kelley R; Atisso, Charles M; Lakshmanan, Mark C; Mody, Reema; Raha, Sohini; Gerstein, Hertzel C
糖尿病
代谢
发表日期：2021
文献求助 收藏

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial

度拉糖肽在老年患者中的疗效和安全性：REWIND试验的事后分析

期刊:Journal of Clinical Endocrinology & Metabolism
影响因子:5.1
doi:10.1210/clinem/dgab065
Riddle, Matthew C; Gerstein, Hertzel C; Xavier, Denis; Cushman, William C; Leiter, Lawrence A; Raubenheimer, Peter J; Atisso, Charles M; Raha, Sohini; Varnado, Oralee J; Konig, Manige; Lakshmanan, Mark; Franek, Edward
发表日期：2021
文献求助 收藏

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

REWIND试验中接受度拉糖肽治疗的2型糖尿病合并心血管危险因素患者的心血管或致命事件总数：一项事后分析

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-020-01179-1
Dagenais, Gilles R; Rydén, Lars; Leiter, Lawrence A; Lakshmanan, Mark; Dyal, Leanne; Probstfield, Jeffrey L; Atisso, Charles Messan; Shaw, Jonathan E; Conget, Ignacio; Cushman, William C; Lopez-Jaramillo, Patricio; Lanas, Fernando; Munoz, Ernesto German Cordona; Pirags, Valdis; Pogosova, Nana; Basile, Jan; Sheu, Wayne H H; Temelkova-Kurktschiev, Theodora; Raubenheimer, Peter J; Keltai, Matyas; Hall, Stephanie; Pais, Prem; Colhoun, Helen M; Riddle, Matthew C; Gerstein, Hertzel C
糖尿病
代谢
发表日期：2020
文献求助 收藏

Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results

胰高血糖素样肽-1受体激动剂治疗心血管结局的试验：研究设计、人群和结果的比较

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.14165
Pantalone, Kevin M; Munir, Kashif; Hasenour, Clinton M; Atisso, Charles M; Varnado, Oralee J; Maldonado, Juan M; Konig, Manige
信号转导
发表日期：2020
文献求助 收藏

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

每周一次度拉糖肽治疗2型糖尿病的心血管安全性：一项预先设定的、前瞻性裁定的心血管事件荟萃分析

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-016-0355-z
Ferdinand, Keith C; Botros, Fady T; Atisso, Charles M; Sager, Philip T
糖尿病
代谢
发表日期：2016
文献求助 收藏